The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-κB function

Journal of Immunology

Volumn 163, Issue 7, 1999, Pages 3928-3935

  Pahlevan, Ali A ^a,c   Wright, David J M ^a   Andrews, Caroline ^c   George, Kathleen M ^b   Small, Pamela L C ^b   Foxwell, Brian M ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; PHORBOL ESTER; TOXIN; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ARTICLE; CELL ADHESION; CELL DEATH; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNE RESPONSE; MONOCYTE; MYCOBACTERIUM ULCERANS; NONHUMAN; PRIORITY JOURNAL; SKIN NECROSIS; T LYMPHOCYTE;

ANIMALS; APOPTOSIS; BACTERIAL TOXINS; CYTOKINES; EXOTOXINS; GUINEA PIGS; HUMANS; IMMUNITY, NATURAL; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; L CELLS (CELL LINE); LIPIDS; MICE; MONOCYTES; MYCOBACTERIUM ULCERANS; NF-KAPPA B; SOLUBILITY; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033214405     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Meyers, W. M., N. Tignokpa, G. B. Priuli, and F. Portaels. 1996. Mycobacterium ulcerans infection (Buruli ulcer): first reported patients in Togo. Br. J. Dermatol. 134:1116.
2. Dodge, O. G. 1964. Mycobacterial skin ulcer in Uganda: histopathological and experimental aspects. J. Pathol. Bacteriol. 88:167.
3. Connor, D. H., and F. Lunn. 1966. Buruli ulceration: a clinicopathologic study of 38 Ugandans with M. ulcerans ulceration. Arch. Pathol. 81:183.
4. Connor, D. H., and F. Lunn. 1965. Mycobacterium ulcerans infection. Int. J. Leprosy 33:698.
5. Connor, D. H., W. M. Meyers, and R. E. Krieg. 1976. Infection by Mycobacterium ulcerans. Armed Forces Institute of Pathology, Washington, DC.
6. Hayman, J. 1993. Out of Africa: observations on the histopathology of Mycobacterium ulcerans infection. J. Clin. Pathol. 46:5.
7. Krieg, R. E., W. T. Hockmeyer, and D. H. Connor. 1974. Toxin of Mycobacterium ulcerans: production and effects in guinea pig skin. Arch. Dermatol. 110:783.
8. Hockmeyer, W. T., R. E. Krieg, M. Reich, and R. D. Johnson. 1978. Further characterization of Mycobacterium ulcerans toxin. Infect. Immun. 21:124.
9. Read, J. K., C. M. Heggie, W. M. Meyers, and D. H. Connor. 1974. Cytotoxic activity of Mycobacterium ulcerans. Infect. Immun. 9:1114.
10. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248.
11. George, K. M., L. P. Barker, D. M. Welty, and P. L. Small. 1998. Partial purification and characterization of biological effects of a lipid toxin produced by Mycobacterium ulcerans. Infect. Immun. 66:587.
12. Mattila, P. S., K. S. Ullman, S. Fiering, E. A. Emmel, M. McCutcheon, G. R. Crabtree, and L. A. Herzenberg. 1990. The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. EMBO J. 9:4425.
13. + Th1 cells pro-inflammatory or anti-inflammatory? The ratio of IL-10 to IFN-γ or IL-2 determines their function. Int. Immunol. 7:1287.
14. Cohen, S. B. 1995. IL-10 and IL-3 synergize to cause proliferation of human T cells. Immunology 85:351.
15. Williams, L. M., D. L. Gibbons, A. Gearing, R. N. Maini, M. Feldmann, and F. M. Brennan. 1996. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF α processing in RA synovial membrane cell cultures. J. Clin. Invest. 97:2833.
16. Espevik, T., and J. Nissen-Meyer. 1986. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods 95:99.
17. Abrams, J. S., M. G. Roncarolo, H. Yssel, U. Andersson, G. J. Gleich, and J. E. Silver. 1992. Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol. Rev. 127:5.
18. Clarke, C. J., A. Hales, A. Hunt, and B. M. Foxwell. 1998. IL-10-mediated suppression of TNF-α production is independent of its ability to inhibit NF-κB activity. Eur. J. Immunol. 28:1719.
19. Fried, J., A. G. Perez, and B. D. Clarkson. 1978. Rapid hypotonic method for flow cytofluorometry of monolayer cell cultures. Some pitfalls in staining and data analysis. J. Histochem. Cytochem. 26:921.
20. Nicoletti, I., G. Migliorati, M. C. Pagliacci, F. Grignani, and C. Riccardi. 1991. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139:271.
21. Uganda-Buruli-Group. 1969. BCG vaccination against Mycobacterium ulcerans infection (Buruli ulcer). Lancet 1:111.
22. Stanford, J. L., W. D. Revill, W. J. Gunthorpe, and J. M. Grange. 1975. The production and preliminary investigation of Burulin, a new skin test reagent for Mycobacterium ulcerans infection. J. Hyg. 74:7.
23. Pimsler, M., T. A. Sponsler, and W. M. Meyers. 1988. Immunosuppressive properties of the soluble toxin from Mycobacterium ulcerans. J. Infect. Dis. 157:577.
24. Katsen, A. D., B. Vollmar, P. Mestres-Ventura, and M. D. Menger. 1998. Cell surface and nuclear changes during TNF-α-induced apoptosis in WEHI 164 murine fibrosarcoma cells: a correlative light, scanning, and transmission electron microscopical study. Virchows Arch. 433:75.
25. May, M. J., and S. Ghosh. 1998. Signal transduction through NF-κB. Immunol. Today 19:80.
26. George, K. M., D. Chatterjee, G. Gunawardana, D. Welty, J. Hayman, R. Lee, and P. L. Small. 1999. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283:854.
27. Vanden Berghe, W., S. Plaisance, E. Boone, K. De Bosscher, M. L. Schmitz, W. Fiers, and G. Haegeman. 1998. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-κB p65 transactivation mediated by tumor necrosis factor. J. Biol. Chem. 273:3285.
28. Fiers, W. 1991. Tumor necrosis factor: characterization at the molecular, cellular and in vivo level. FEBS Lett. 285:199.
29. Dayer, J. M., and D. Burger. 1994. Interleukin-1, tumor necrosis factor and their specific inhibitors. Eur. Cytokine Netw. 5:563.
30. Ding, A. H., C. F. Nathan, and D. J. Stuehr. 1988. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J. Immunol. 141:2407.
31. Bermudez, L. E., and L. S. Young. 1988. Tumor necrosis factor, alone or in combination with IL-2, but not IFN-γ, is associated with macrophage killing of Mycobacterium avium complex. J. Immunol. 140:3006.
32. MacCallum, P., J. C. Tolhurst, G. Buckle, and H. A. Sissons. 1948. A new mycobacterial infection in man. J. Pathol. Bacteriol. 60:93.
33. Barnes, P. F., S. Lu, J. S. Abrams, E. Wang, M. Yamamura, and R. L. Modlin. 1993. Cytokine production at the site of disease in human tuberculosis. Infect. Immun. 61:3482.
34. Hsu, H., J. Xiong, and D. V. Goeddel. 1995. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation. Cell 81:495.
35. Hsu, H., J. Huang, H. B. Shu, V. Baichwal, and D. V. Goeddel. 1996. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4:387.
36. Malinin, N. L., M. P. Boldin, A. V. Kovalenko, and D. Wallach. 1997. MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature 385:540.
37. Hsu, H., H. B. Shu, M. G. Pan, and D. V. Goeddel. 1996 TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84:299.
38. Ghosh, S., M. J. May, and E. B. Kopp. 1998. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16:225.
39. ras and protein kinase Czeta in primary endothelial cells. J. Biol. Chem. 274:13594.
40. Bird, T. A., K. Schooley, S. K. Dower, H. Hagen, and G. D. Virca. 1997. Activation of nuclear transcription factor NF-κB by interleukin-1 is accompanied by casein kinase II-mediated phosphorylation of the p65 subunit. J. Biol. Chem. 272:32606.
41. Diehl, J. A., W. Tong, G. Sun, and M. Hannink. 1995. Tumor necrosis factor-α-dependent activation of a RelA homodimer in astrocytes: increased phosphorylation of RelA and MAD-3 precede activation of RelA. J. Biol. Chem. 270:2703.
42. Finco, T. S., J. K. Westwick, J. L. Norris, A. A. Beg, C. J. Der, and A. S. Baldwin, Jr. 1997. Oncogenic Ha-Ras-induced signaling activates NF-κB transcriptional activity, which is required for cellular transformation. J. Biol. Chem. 272:24113.
43. Naumann, M., and C. Scheidereit. 1994. Activation of NF-κB in vivo is regulated by multiple phosphorylations. EMBO J. 13:4597.
44. Schmitz, M. L., M. A. dos Santos Silva, and P. A. Baeuerle. 1995. Transactivation domain 2 (TA2) of p65 NF-κB: aimilarity to TA1 and phorbol ester-stimulated activity and phosphorylation in intact cells. J. Biol. Chem. 270:15576.
45. Wang, D., and A. S. Baldwin, Jr. 1998. Activation of nuclear factor-KB-dependent transcription by tumor necrosis factor-α is mediated through phosphorylation of RelA/p65 on serine 529. J. Biol. Chem. 273:29411.
46. Carpentier, I., W. Declercq, N. L. Malinin, D. Wallach, W. Fiers, and R. Beyaert. 1998. TRAF2 plays a dual rote in NF-κB-dependent gene activation by mediating the TNF-induced activation of p38 MAPK and IκB kinase pathways. FEBS Lett. 425:195.
47. Jaeschke, H., M. A. Fisher, J. A. Lawson, C. A. Simmons, A. Farhood, and D. A. Jones. 1998. Activation of caspase 3 (CPP32)-like proteases is essential for TNF-α-induced hepatic parenchymal cell apoptosis and neutrophil-mediated necrosis in a murine endotoxin shock model. J. Immunol. 160:3480.
48. Yang, R. B., M. R. Mark, A. Gray, A. Huang, M. H. Xie, M. Zhang, A. Goddard, W. I. Wood, A. L. Gurney, and P. J. Godowski. 1998. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 395:284.
49. Poltorak, A., X. He, I. Smirnova, M. Y. Liu, C. V. Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085.
50. Wesche, H., W. J. Henzel, W. Shillinglaw, S. Li, and Z. Cao. 1997. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex Immunity 7:837.
51. Croston, G. E., Z. Cao, and D. V. Goeddel. 1995. NF-κB activation by interleukin-1 (IL-I) requires an IL-1 receptor-associated protein kinase activity. J. Biol. Chem. 270:16514.
52. Cao, Z., J. Xiong, M. Takeuchi, T. Kurama, and D. V. Goeddel. 1996. TRAF6 is a signal transducer for interleukin-1. Nature 383:443.
53. Cao, Z., W. J. Henzel, and X. Gao. 1996. IRAK: a kinase associated with the interleukin-1 receptor. Science 271:1128.
54. Stylianou, E., and J. Saklatvala. 1998. Interleukin-1. Int. J. Biochem. Cell Biol. 30:1075.
55. Calleja, C. J., M. Pascussi, J. C. J. C. Mani, P. P. Maurel, and M. J. Vilarem. 1998. The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor. Nat. Med. 4:92.
56. Bellahsène, A., and A. Forsgren. 1980. Effect of rifampin on the immune response in mice. Infect. Immun. 27:15.
57. Chemushenko, E. F., and V. A. Shiniberov. 1981. Effect of rifampicin on body immunological reactivity. Antibiotiki 26:743.
58. Demkow, U., D. Radomska, J. Chorostowska-Wynimko, and E. Skopinska-Rózringewska. 1998. The influence of rifampicin on selected parameters of immunologic response. Pneumonol. I Alergol. Polska 66:45.
59. Lai, J. H., and T. H. Tan. 1994. CD28 signaling causes a sustained down-regulation of IκBα which can be prevented by the immunosuppressant rapamycin.
60. Dinarello, C. A. 1996. Biologic basis for interleukin-1 in disease. Blood 87:2095.